You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00412100 ↗ Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation Completed Mundipharma Research GmbH & Co KG Phase 3 2006-04-01 The primary objective is to demonstrate that patients taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.
NCT00412152 ↗ Oxycodone-naloxone in Relieving Opioid-related Constipation Completed Mundipharma Research GmbH & Co KG Phase 3 2006-01-01 The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.
NCT00513656 ↗ A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain Completed Mundipharma Research GmbH & Co KG Phase 2 2007-09-01 The purpose of this study is to test the oxycodone/naloxone combination compared to oxycodone alone in patient's specific type of "chronic cancer pain".
NCT00784810 ↗ A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis Completed Napp Pharmaceuticals Limited Phase 4 2009-02-01 The purpose of this study is to compare oxycodone/naloxone combination tablet and codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or pain due to osteoarthritis.
NCT00902837 ↗ OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects Completed Mundipharma Research GmbH & Co KG Phase 3 2009-05-01 The primary objectives are - to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function. - to demonstrate that subjects with moderate to severe OA pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone
NCT00944697 ↗ A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diab Completed Mundipharma Research GmbH & Co KG Phase 2 2009-07-01 To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone.
NCT01014559 ↗ Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients Terminated Mundipharma SAS Phase 3 2010-02-01 The primary objective of this trial is to study the efficacy of oxycodone/naloxone prolonged release tablets (OXN PR), compared to oxycodone prolonged release tablets (Oxy PR), for the reduction of the intensity of opioid-induced constipation symptoms in patients treated for cancer or non-cancer pain.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

Condition Name

Condition Name for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Intervention Trials
Pain 9
Low Back Pain 6
Constipation 5
Cancer 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Intervention Trials
Constipation 11
Pain, Postoperative 8
Opioid-Induced Constipation 7
Low Back Pain 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

Trials by Country

Trials by Country for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Location Trials
United States 121
China 18
Germany 7
Korea, Republic of 6
United Kingdom 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Location Trials
New York 7
New Jersey 5
Massachusetts 5
Ohio 4
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 22
Phase 3 16
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 41
Recruiting 4
Not yet recruiting 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

Sponsor Name

Sponsor Name for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Sponsor Trials
Mundipharma Research GmbH & Co KG 11
Mundipharma Korea Ltd 5
Purdue Pharma LP 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Sponsor Trials
Industry 39
Other 21
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.